Al Dahouk S, Sprague L D, Neubauer H
Federal Institute for Risk Assessment, Diedersdorfer Weg 1, D-12277 Berlin, Germany.
Rev Sci Tech. 2013 Apr;32(1):177-88. doi: 10.20506/rst.32.1.2204.
At present, laboratory diagnosis of human brucellosis is based on isolation of the bacteria from clinical samples followed by standard microbiological tube testing, detection of anti-Brucella antibodies using various serological tests, and the use of molecular methods for the detection of Brucella DNA. None of these diagnostic tools can be used on its own to reliably detect the causative agent. Cultures give a low yield and subsequent phenotypic characterisation is time consuming, meaning that the initiation of adequate antibiotic therapy is frequently delayed. Serological tests seem to be more effective but are not internationally standardised. Moreover, antibodies can remain detectable despite successful therapy, cross-reacting antibodies may occur, and variable cut-offs for different levels of endemicity are lacking. Molecular assays may reduce diagnostic delays in clinical laboratories, but diagnostic criteria for active infection have not yet been defined. This article reviews the latest microbiological methods for the diagnosis of human brucellosis and outlines developments for the future.
目前,人类布鲁氏菌病的实验室诊断基于从临床样本中分离细菌,随后进行标准微生物学试管检测、使用各种血清学检测方法检测抗布鲁氏菌抗体,以及使用分子方法检测布鲁氏菌DNA。这些诊断工具都不能单独用于可靠地检测病原体。培养物的检出率低,后续的表型鉴定耗时,这意味着适当抗生素治疗的启动经常延迟。血清学检测似乎更有效,但尚未实现国际标准化。此外,尽管治疗成功,抗体仍可能被检测到,可能会出现交叉反应抗体,并且缺乏针对不同流行程度的可变临界值。分子检测可能会减少临床实验室的诊断延迟,但活动性感染的诊断标准尚未确定。本文综述了人类布鲁氏菌病诊断的最新微生物学方法,并概述了未来的发展方向。